Nonalcoholic fatty liver disease (NAFLD ... and end-stage liver disease. Hepatocellular carcinoma (HCC) is a documented complication in an as yet unknown percentage of cases of NASH cirrhosis.

CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...

where cancer from another part of the body spreads to the liver. Hepatocellular Carcinoma (HCC) stands out as the predominant form of primary liver cancer, particularly prevalent among individuals ...

Explore how the liver functions, common liver conditions, and tips to maintain liver health through lifestyle changes like ...

A new study reveals that even low-dose, chronic exposure to air pollution can trigger liver inflammation, fibrosis, and metabolic disruptions, increasing the risk of fatty liver disease and other ...

With the increasing prevalence of non-alcoholic fatty liver disease (NAFLD ... especially in lowering the risk of developing hepatocellular carcinoma (HCC) has recently attracted considerable ...

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Fatty liver disease, or hepatic steatosis, occurs when excess fat accumulates in liver cells. Commonly associated with ...